This clinical trial compares a behavioral application (app) called Actify! to a control app (QuitGuide) for improving smoking cessation outcomes in individuals who smoke. Actify! is an app for smoking cessation grounded in behavioral activation therapy. Behavioral activation is an evidence-based treatment designed to modify behavior by increasing positive events and reinforcers, as well as decreasing negative events and consequences. It is frequently used for treating depression and anxiety, and is being considered as a novel strategy for smoking cessation. The Actify! app combines behavioral activation strategies with standard tobacco cessation strategies, and may be more effective than the standard QuitGuide app for improving smoking cessation outcomes.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT07493252.
Locations matching your search criteria
United States
Washington
Seattle
Fred Hutch/University of Washington/Seattle Children's Cancer ConsortiumStatus: Approved
Contact: Jaimee Heffner
Phone: 206-667-7314
PRIMARY OBJECTIVE:
I. Determine the efficacy of Actify! relative to the National Cancer Institute (NCI) QuitGuide app.
SECONDARY OBJECTIVES:
I. Evaluate pre-quit depressive symptoms as a moderator of treatment outcomes.
II. Evaluate behavioral activation and depressive symptoms as theory-based mediators of treatment outcomes.
EXPLORATORY OBJECTIVES:
I. To evaluate differences between Actify! and QuitGuide on treatment satisfaction and utilization.
II. To explore app usage benchmarks for the Actify! app (e.g., number of app logins, total duration of use).
III. To evaluate the relationship between user characteristics (e.g., race, ethnicity, age) and treatment utilization and outcomes.
OUTLINE: Participants are randomized to 1 of 2 arms.
ARM I: Participants use the Actify! app, which helps users identify personal values and meaningful activities, prompts users to schedule and complete meaningful activities, visualizes progress towards meeting activity and smoking-related goals, and provides tailored messages, resources, daily tips, personalized feedback, inspirational messages, and user stories, for 8 weeks on study.
ARM II: Participants use the QuitGuide app, which contains brief quit advice, tools for tracking smokefree days, progress and cravings, guidance on preparing to quit, cravings, withdrawal, and slips, and a mood management feature, for 8 weeks on study.
After completion of study intervention, participants are followed up at 6 months.
Trial PhaseNo phase specified
Trial Typeprevention
Lead OrganizationFred Hutch/University of Washington/Seattle Children's Cancer Consortium
Principal InvestigatorJaimee Heffner
